NCT02452385View on ClinicalTrials.gov

Phase 1 Study of CM082 in Patients With wAMD

PHASE1SuspendedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
Age-Related Macular Degeneration
Interventions
DRUG

CM082 tablet

CM082 tablets taken orally

Trial Locations (6)

100044

Peking University People's Hospital, Beijing

100730

Beijing Hospital, Beijing

Beijing Tongren Hospital，Capital Medical University, Beijing

200080

The First People's Hospital of Shanghai, Shanghai

325027

The Eye Hospital of Wenzhou Medical University, Wenzhou

610041

West China Hospital, Chengdu

Sponsors

Lead Sponsor

AnewPharma
All Listed Sponsors
collaborator

West China Hospital

OTHER

lead

AnewPharma

INDUSTRY

NCT02452385 - Phase 1 Study of CM082 in Patients With wAMD | Biotech Hunter | Biotech Hunter